Transforming Cancer Screening and Diagnosis
Through Research
Innovative liquid biopsy helps in the early detection and diagnosis of cancer
when it matters most
(Cancer Associated Macrophage-Like Cells)
Research on Early Detection of Cancer and Recurrence
Cancer Screening
Residual Disease
Detection of Recurrence
CAMLs
25-300 µm in Size
Present in Cancers of All Stages
Detected in More Than 30 Types of Cancer
Studies to Determine Cancer Aggressiveness
Develop Companion/Complementary Diagnostics
Cancer Diagnostics Research
Research on Monitoring Therapy
Assay Applicable to All Cancers in All Stages
Enhance Patient Selection in Clinical Trials
Provide Real Time Prognosis Information
Monitor Treatment Response
Deliver Tissue-free Companion Diagnostics
Validate Drug Targets
Deliver High Quality Whole DNA for Sequencing
Streamline Drug Development and Clinical Trials
CTCs
(Circulating Tumor Cells)
8-25 µm in Size
Present in Late Stage Cancers
Detected in Breast, Prostate, Colorectal, and Small Cell Lung Cancers
Early Determination of Response to Therapy
Sequential Monitoring of Tumor Marker Status During Therapy
Monitoring change of PD-L1 Expression
